Mechanism of action of a novel STAT3 inhibitor and its effect on leukemic stem cell
| Project/Area Number |
23591381
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | STAT阻害剤 / 分子標的薬 / ヒト化マウス / 白血病 / STAT3 / 抗癌剤 / 白血病モデルマウス / 抗がん剤 |
|---|
| Research Abstract |
STAT proteins are transcription factors that mediate cell proliferation and differentiation. Aberrant signals of STAT are strongly involved in cancer. We demonstrated that a novel STAT inhibitor, OPB-31121, strongly inhibited STAT3 and STAT5 phosphorylation, and induced significant growth inhibition in various hematopoietic malignant cells. OPB-31121 was particularly effective against leukemia harboring BCR-ABL, FLT3/ITD, and JAK2 V617F. We showed the significant anti-tumor effect of OPB-31121 against human leukemia cells using patient-derived xenograft model.
|
Report
(4 results)
Research Products
(20 results)
